{
  "source": "PA-Notification-Calquence.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1237-9\nProgram Prior Authorization/Notification\nMedication Calquence® (acalabrutinib)\nP&T Approval Date 12/2017, 12/2018, 12/2019, 4/2020, 5/2021, 5/2022, 5/2023, 5/2024,\n3/2025\nEffective Date 6/1/2025\n1. Background:\nCalquence (acalabrutinib) is a kinase inhibitor indicated:\n• In combination with bendamustine and rituximab for the treatment of adult patients with\npreviously untreated mantle cell lymphoma (MCL) who are ineligible for autologous\nhematopoietic stem cell transplantation (HSCT).\n• For the treatment of adult patients with MCL who have received at least one prior therapy.\n• For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small\nlymphocytic lymphoma (SLL).\nThe National Comprehensive Cancer Network (NCCN) recommends the use of Calquence for the\ntreatment of B-cell lymphomas, including splenic and nodal marginal zone lymphoma, extranodal\nmarginal zone lymphoma (EMZL) of the stomach, extranodal marginal zone lymphoma of\nnongastric sites (noncutaneous), and Waldenström macroglobulinemia/lymphoplasmacytic\nlymphoma.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the notification\ncriteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Calquence will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Mantle Cell Lymphoma (MCL)\n1. Initial Authorization\na. Calquence will be approved based on the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) B",
    "ation will be issued for 12 months.\nB. Mantle Cell Lymphoma (MCL)\n1. Initial Authorization\na. Calquence will be approved based on the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) Both of the following:\n(a) Diagnosis of mantle cell lymphoma (MCL)\n-AND-\n(b) One of the following:\ni. All of the following:\n• Patient has not received prior therapy (e.g., bortezomib, rituximab) for\nMCL\n• Patient is ineligible for autologous hematopoietic stem cell\ntransplantation (HSCT)\n• Used in combination with bendamustine and rituximab\n-OR-\nii. Patient has received at least one prior therapy for MCL (e.g., bortezomib,\nrituximab)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Calquence will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Calquence therapy\nAuthorization will be issued for 12 months.\nC. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\n1. Initial Authorization\na. Calquence will be approved based on the following criterion:\n(1) Diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Calquence will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Calquence therapy\nAuthorization will be issued for 12 months.\nD. B-Cell Lymphomas\n© 2025 UnitedHealthcare Services, Inc.\n2\n1. Initial Authorization\na. Calquence will be approved based on the following criteria:\n(1) Diagnosis of one of the following:\n(a) Nodal Marginal Zone Lymphoma\n(b) Extranodal Marginal Zone Lymphoma (EMZL) of the stomach\n(c) Splenic Marginal Zone Lymphoma\n(d) Extranodal Marginal Zone Lymphoma of Nongastric Sites (Non-cutaneous)\n-AND-\n(2) Disease is recurrent, relapsed, refractory, or progressive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Calquence will be approved based on the following criterion:\n(1) Patient does not show evidence of progre",
    ", refractory, or progressive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Calquence will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Calquence therapy\nAuthorization will be issued for 12 months.\nE. Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma\n1. Initial Authorization\na. Calquence will be approved based on the following criteria:\n(1) Both of the following:\n(a) Diagnosis of Waldenström Macroglobulinemia / Lymphoplasmacytic\nLymphoma\n-AND-\n(b) One of the following:\ni. Patient did not respond to primary therapy\nii. Disease is relapsed or progressive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Calquence will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n3\n(1) Patient does not show evidence of progressive disease while on Calquence therapy\nAuthorization will be issued for 12 months.\nF. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. January 2025.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/prof",
    "nces:\n1. Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. January 2025.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed February 12, 2025.\nProgram Prior Authorization/Notification – Calquence (acalabrutinib)\nChange Control\n12/2017 New program\n12/2018 Annual review. Added criteria for Chronic Lymphocytic\nLeukemia/Small Lymphocytic Lymphoma.\n12/2019 Annual review. No changes to coverage criteria.\n4/2020 Updated criteria to reflect FDA label change for CLL/SLL. Added\nNCCN recommended regimens standard language.\n5/2021 Annual review. Added criteria for B-cell lymphomas and Waldenström\nMacroglobulinemia according to NCCN guidelines.\n5/2022 Annual review with no change to clinical criteria. Updated background\nand reference.\n5/2023 Annual review. Changed classification of Gastric MALT lymphoma to\nExtranodal marginal zone lymphoma (EMZL) of the stomach and\nNongastric MALT Lymphoma (Noncutaneous) to Extranodal Marginal\nZone Lymphoma of Nongastric Sites (Noncutaneous) per NCCN\nguidelines. Added state mandate. Removed Imbruvica criteria. Updated\nbackground and references.\n© 2025 UnitedHealthcare Services, Inc.\n4\n5/2024 Annual review with no change to clinical criteria. Updated reference.\n3/2025 Updated criteria to reflect FDA indication for patients with previously\nuntreated MCL who are ineligible for HSCT. Updated background and\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n5"
  ]
}